Stockscreener 앱 받기
2.305
5.53%
-0.135
시장 영업 전:
2.33
0.025
+1.08%
전일 마감가:
$2.44
열려 있는:
$2.42
하루 거래량:
1.28M
Relative Volume:
0.53
시가총액:
$430.21M
수익:
$7.12M
순이익/손실:
$-24.17M
주가수익비율:
-9.47
EPS:
-0.2434
순현금흐름:
$-41.95M
1주 성능:
-5.14%
1개월 성능:
+1.54%
6개월 성능:
+51.64%
1년 성능:
+319.09%
1일 변동 폭
$2.30
$2.47
1주일 범위
$2.30
$2.53
52주 변동 폭
$0.475
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.305 | 430.21M | 7.12M | -24.17M | -41.95M | -0.2434 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 개시 | Roth Capital | Buy |
| 2025-11-17 | 개시 | Leerink Partners | Outperform |
| 2025-10-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-08 | 재개 | B. Riley Securities | Buy |
| 2024-06-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 개시 | B. Riley Securities | Buy |
| 2024-04-29 | 개시 | H.C. Wainwright | Buy |
| 2024-04-05 | 개시 | Wedbush | Outperform |
| 2023-12-21 | 개시 | BTIG Research | Buy |
| 2023-10-13 | 개시 | Oppenheimer | Outperform |
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Canada
Ovid Therapeutics (OVID) Edges Higher, Holding Above Key Support ZoneMoving Average Ribbon - dars.gov.et
FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc - GuruFocus
Ovid Therapeutics names new chief business officer By Investing.com - Investing.com Nigeria
Ovid Therapeutics Appoints New Executives to Drive Strategic Growth - sekbernews.id
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer - Yahoo Finance
Ovid Therapeutics appoints Charles Carter as new CFO - The Globe and Mail
Form 4 Ovid Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Ovid Therapeutics (ticker: OVID) grants CFO 50,000 RSUs vesting 2027-2028 - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) CFO reports 44,375 shares and long-dated stock options - Stock Titan
Ovid Therapeutics Says Carter Has More Than 30 Yrs of Experience Across Finance, Strategy, Operational Leadership >OVID - Moomoo
PR News | On the Move: Ovid Therapeutics Hires Fort as CSOWed., Jul. 8, 2026 - O'Dwyer's PR
Ovid Therapeutics names new chief business officer - Investing.com
Ovid Therapeutics: Victoria Fort Promoted to Chief Strategy Officer >OVID - Moomoo
Federated Hermes (NASDAQ: OVID) holds 7.74M shares, 4.15% disclosed - Stock Titan
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo
Ovid Therapeutics names Charles Carter as CFO as Jeffrey Rona transitions from finance roles - TradingView
New Ovid Therapeutics (NASDAQ: OVID) CFO named as Rona transitions to consultant - Stock Titan
Ovid Therapeutics Strengthens Executive Leadership Team to - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally - Seeking Alpha
Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329, TSC/IS Expansions - Seeking Alpha
Ovid Therapeutics upgraded to Buy as OV329 shows strong safety and advances in epilepsy treatment trials. - Pluang
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth - Sahm
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Value Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Microcap Value Benchmark Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell Microcap Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Value Benchmark - marketscreener.com
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID) - TradingView
OVID Forecast — Price Target — Prediction for 2027 - TradingView
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
1OT Forecast — Price Target — Prediction for 2027 - TradingView
Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT) - TradingView
Price to book forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Price to earnings forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Price to sales forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Sahm
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ovid Therapeutics (OVID) Shares Decline 6.2% as Stock Tests Support Near $2.16Mid Cap Momentum - DonanımHaber
OVIDOvid Therapeutics Inc Latest SEC Filings - Finviz
OVID Q1 2026 Earnings: Narrower-than-Expected Loss But Stock Declines 6.2%Annual Financial Report - dars.gov.et
Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options - Stock Titan
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
3.77%
자본화:
|
볼륨(24시간):